MetaVia Inc. is a clinical-stage biotechnology company headquartered in Cambridge, Massachusetts, focused on developing multi-modal, disease-modifying therapies for serious metabolic and neurological conditions. The company concentrates on cardiometabolic diseases, including obesity and Metabolic Dysfunction-Associated Steatohepatitis (MASH), as well as select central nervous system disorders. Its current pipeline includes DA-1726, being developed for obesity, and vanoglipel (DA-1241), a GPR119 agonist targeting MASH with potential relevance to Type 2 Diabetes Mellitus through modulation of gut hormones such as GLP-1, GIP, and peptide YY. MetaVia also develops ANA001, a proprietary oral niclosamide formulation, Gemcabene for acute indications including infectious and inflammatory settings, NB-01 for painful diabetic neuropathy, and NB-02 aimed at symptoms of cognitive impairment in neurodegenerative diseases. Operating within the biotechnology and health technology sectors, MetaVia plays a specialized role in addressing complex, high-burden diseases where there is significant medical need for new therapeutic options.